Insider Trading Alert - KMI, REGN And DRH Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, Feb. 21, 2014, 123 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $98.40 to $9,872,759.00.

Highlighted Stocks Traded by Insiders:

Kinder Morgan (KMI) - FREE Research Report

Kinder Richard D who is Chairman and CEO at Kinder Morgan bought 100,000 shares at $32.97 on Feb. 21, 2014. Following this transaction, the Chairman and CEO owned 231.7 million shares meaning that the stake was reduced by 0.04% with the 100,000-share transaction.

The shares most recently traded at $32.24, down $0.73, or 2.27% since the insider transaction. Historical insider transactions for Kinder Morgan go as follows:

  • 4-Week # shares bought: 20,000
  • 12-Week # shares bought: 849,309
  • 24-Week # shares bought: 1.3 million

The average volume for Kinder Morgan has been 6.2 million shares per day over the past 30 days. Kinder Morgan has a market cap of $34.4 billion and is part of the basic materials sector and energy industry. Shares are down 8.25% year-to-date as of the close of trading on Friday.

Kinder Morgan, Inc. owns and operates energy transportation and storage assets in the United States and Canada. The company operates in six segments: Natural Gas Pipelines, Products Pipelines KMP, CO2 KMP, Terminals KMP, Kinder Morgan Canada KMP, and Other. The stock currently has a dividend yield of 4.94%. The company has a P/E ratio of 28.9. Currently there are 6 analysts that rate Kinder Morgan a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on KMI - FREE

TheStreet Quant Ratings rates Kinder Morgan as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, compelling growth in net income, growth in earnings per share, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Kinder Morgan Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Regeneron Pharmaceuticals (REGN) - FREE Research Report

Goldstein Joseph L who is Director at Regeneron Pharmaceuticals sold 1,000 shares at $326.99 on Feb. 21, 2014. Following this transaction, the Director owned 1,000 shares meaning that the stake was reduced by 50% with the 1,000-share transaction.

The shares most recently traded at $343.00, up $16.01, or 4.67% since the insider transaction. Historical insider transactions for Regeneron Pharmaceuticals go as follows:

  • 4-Week # shares sold: 1,000
  • 12-Week # shares sold: 14,000
  • 24-Week # shares sold: 19,000

The average volume for Regeneron Pharmaceuticals has been 891,400 shares per day over the past 30 days. Regeneron Pharmaceuticals has a market cap of $32.1 billion and is part of the health care sector and drugs industry. Shares are up 21.7% year-to-date as of the close of trading on Friday.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. The company has a P/E ratio of 86.0. Currently there are 9 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on REGN - FREE

TheStreet Quant Ratings rates Regeneron Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income and feeble growth in the company's earnings per share. Get the full Regeneron Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Diamondrock Hospitality Company (DRH) - FREE Research Report

Mccarten William W who is Director at Diamondrock Hospitality Company sold 46,101 shares at $12.25 on Feb. 21, 2014. Following this transaction, the Director owned 333,712 shares meaning that the stake was reduced by 12.14% with the 46,101-share transaction.

The shares most recently traded at $12.43, up $0.18, or 1.45% since the insider transaction. Historical insider transactions for Diamondrock Hospitality Company go as follows:

  • 4-Week # shares sold: 57,647
  • 12-Week # shares sold: 72,388
  • 24-Week # shares sold: 132,388

The average volume for Diamondrock Hospitality Company has been 1.6 million shares per day over the past 30 days. Diamondrock Hospitality Company has a market cap of $2.4 billion and is part of the financial sector and real estate industry. Shares are up 6.58% year-to-date as of the close of trading on Friday.

DiamondRock Hospitality Company, a lodging focused real estate company, owns premium hotels and resorts in North America. The stock currently has a dividend yield of 2.76%. The company has a P/E ratio of 61.5. Currently there are 5 analysts that rate Diamondrock Hospitality Company a buy, no analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DRH - FREE

TheStreet Quant Ratings rates Diamondrock Hospitality Company as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, reasonable valuation levels, good cash flow from operations and compelling growth in net income. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Diamondrock Hospitality Company Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Billionaire Investor Tim Draper Explains Why Bitcoin Will Hit $250,000 in 2022

Billionaire Investor Tim Draper Explains Why Bitcoin Will Hit $250,000 in 2022

To Think a Trade War's Still Just a Threat Is the Dumbest Thing on Wall Street

To Think a Trade War's Still Just a Threat Is the Dumbest Thing on Wall Street

M&A Trends Still on Investors' Minds Despite Worries Over Tariffs -- ICYMI

M&A Trends Still on Investors' Minds Despite Worries Over Tariffs -- ICYMI

Dow Falls as U.S. Imposes Tariffs on $50 Billion of Chinese Goods

Dow Falls as U.S. Imposes Tariffs on $50 Billion of Chinese Goods

General Motors Spikes on Report It's Considering Listing Shares of Cruise Unit

General Motors Spikes on Report It's Considering Listing Shares of Cruise Unit